Form 4: TBPH Exec Sells Shares for Tax Obligations

Aine Miller, SVP, Development & Head of IRE Office at Theravance Biopharma, disposed of 6,989 ordinary shares to satisfy tax obligations from restricted stock unit vesting.

Summary

• Aine Miller, SVP, Development & Head of IRE Office at Theravance Biopharma, Inc. (TBPH), reported a transaction involving ordinary shares.
• On November 20, 2025, Miller disposed of 6,989 ordinary shares.
• The transaction was coded 'F', indicating shares were withheld by the issuer to satisfy tax obligations arising from the vesting of previously granted restricted stock units.
• The shares were valued at $17.9 per share for the purpose of this transaction.
• Following this transaction, Aine Miller beneficially owns 201,012 ordinary shares directly.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, a pre-arranged contract for the purchase or sale of equity securities.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary disposition of shares to cover tax liabilities upon the vesting of restricted stock units, which is a neutral event and does not reflect management's sentiment about the company's future prospects.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction, as it is a report of a past insider transaction.

Industry Context

This Form 4 filing reports a routine insider transaction related to executive compensation and tax obligations, which is a common occurrence across all industries, particularly in companies that grant restricted stock units as part of their compensation packages. It does not provide insights into broader industry trends or competitive landscape.

Related Party Transactions

• The share withholding transaction was conducted with the issuer (Theravance Biopharma, Inc.) to satisfy tax obligations, rather than through an open market sale.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes and does not signal a change in company fundamentals or management's discretionary view of the stock.
• Employees: Reflects standard executive compensation practices involving restricted stock units and associated tax handling.

Key Dates

Recommendation

This Form 4 reports a routine, non-discretionary sale of shares by an executive to cover tax obligations upon the vesting of restricted stock units. Such transactions are common and do not typically indicate a change in the company's fundamental outlook or the executive's confidence in the company. Therefore, it provides no new information that would warrant a change in investment recommendation; a 'hold' stance is maintained based solely on this filing.

Keywords

Theravance Biopharma, TBPH, Form 4, Insider Transaction, Stock Sale, Tax Withholding, Restricted Stock Units, Corporate Governance